APO Research
Talk to an analyst

APO RESEARCH · REPORT

Acute Hepatic Porphyria Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Acute Hepatic Porphyria Drug Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchAcute Hepatic Porphyria Drug Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Acute Hepatic Porphyria Drug Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Acute Hepatic Porphyria Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Acute Hepatic Porphyria Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Acute Hepatic Porphyria Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Acute Hepatic Porphyria Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Acute Hepatic Porphyria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Acute Hepatic Porphyria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Acute Hepatic Porphyria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Acute Hepatic Porphyria Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Acute Hepatic Porphyria Drug market include Alnylam Pharmaceuticals and Recordati Rare Diseases among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Acute Hepatic Porphyria Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Acute Hepatic Porphyria Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Acute Hepatic Porphyria Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Acute Hepatic Porphyria Drug market.

Acute Hepatic Porphyria Drug Segment by Company

Alnylam Pharmaceuticals

Recordati Rare Diseases

Acute Hepatic Porphyria Drug Segment by Type

350 Mg

313 Mg

Acute Hepatic Porphyria Drug Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Others

Acute Hepatic Porphyria Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Acute Hepatic Porphyria Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Acute Hepatic Porphyria Drug key companies, revenue, market share, and recent developments.

3. To split the Acute Hepatic Porphyria Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Acute Hepatic Porphyria Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Acute Hepatic Porphyria Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Acute Hepatic Porphyria Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Acute Hepatic Porphyria Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Acute Hepatic Porphyria Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Acute Hepatic Porphyria Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Acute Hepatic Porphyria Drug industry.

Chapter 3: Detailed analysis of Acute Hepatic Porphyria Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Acute Hepatic Porphyria Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Acute Hepatic Porphyria Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Acute Hepatic Porphyria Drug Industry Trends Table 2. Acute Hepatic Porphyria Drug Industry Drivers Table 3. Acute Hepatic Porphyria Drug Industry Opportunities and Challenges Table 4. Acute Hepatic Porphyria Drug Industry Restraints Table 5. Global Acute Hepatic Porphyria Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Acute Hepatic Porphyria Drug Revenue Share by Company (2021-2026) Table 7. Global Acute Hepatic Porphyria Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Acute Hepatic Porphyria Drug Key Company Manufacturing Base & Headquarters Table 9. Global Acute Hepatic Porphyria Drug Company, Product Type & Application Table 10. Global Acute Hepatic Porphyria Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Acute Hepatic Porphyria Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 350 Mg Table 15. Significant Companies of 313 Mg Table 16. Global Acute Hepatic Porphyria Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Acute Hepatic Porphyria Drug Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Acute Hepatic Porphyria Drug Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Acute Hepatic Porphyria Drug Sales Value Share by Type (2021-2026) Table 20. Global Acute Hepatic Porphyria Drug Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Retail Pharmacy Table 22. Significant Companies of Online Pharmacy Table 23. Significant Companies of Hospital Pharmacy Table 24. Significant Companies of Others Table 25. Global Acute Hepatic Porphyria Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Acute Hepatic Porphyria Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Acute Hepatic Porphyria Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Acute Hepatic Porphyria Drug Sales Value Share by Application (2021-2026) Table 29. Global Acute Hepatic Porphyria Drug Sales Value Share by Application (2027-2032) Table 30. Global Acute Hepatic Porphyria Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Acute Hepatic Porphyria Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Acute Hepatic Porphyria Drug Sales Value Share by Region (2021-2026) Table 33. Global Acute Hepatic Porphyria Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Acute Hepatic Porphyria Drug Sales Value Share by Region (2027-2032) Table 35. Global Acute Hepatic Porphyria Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Acute Hepatic Porphyria Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Acute Hepatic Porphyria Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Acute Hepatic Porphyria Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Acute Hepatic Porphyria Drug Sales Value Market Share by Country (2027-2032) Table 40. Alnylam Pharmaceuticals Company Information Table 41. Alnylam Pharmaceuticals Business Overview Table 42. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product Portfolio Table 44. Alnylam Pharmaceuticals Recent Development Table 45. Recordati Rare Diseases Company Information Table 46. Recordati Rare Diseases Business Overview Table 47. Recordati Rare Diseases Acute Hepatic Porphyria Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Recordati Rare Diseases Acute Hepatic Porphyria Drug Product Portfolio Table 49. Recordati Rare Diseases Recent Development Table 50. Research Programs/Design for This Report Table 51. Authors List of This Report Table 52. Secondary Sources Table 53. Primary Sources List of Figures Figure 1. Acute Hepatic Porphyria Drug Product Image Figure 2. Global Acute Hepatic Porphyria Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Acute Hepatic Porphyria Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Acute Hepatic Porphyria Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 350 Mg Image Figure 8. 313 Mg Image Figure 9. Global Acute Hepatic Porphyria Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Acute Hepatic Porphyria Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Acute Hepatic Porphyria Drug Sales Value Share by Type (2021-2032) Figure 12. Retail Pharmacy Image Figure 13. Online Pharmacy Image Figure 14. Hospital Pharmacy Image Figure 15. Others Image Figure 16. Global Acute Hepatic Porphyria Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Acute Hepatic Porphyria Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Acute Hepatic Porphyria Drug Sales Value Share by Application (2021-2032) Figure 19. Global Acute Hepatic Porphyria Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Acute Hepatic Porphyria Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Acute Hepatic Porphyria Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Acute Hepatic Porphyria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Acute Hepatic Porphyria Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Acute Hepatic Porphyria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Acute Hepatic Porphyria Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Acute Hepatic Porphyria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Acute Hepatic Porphyria Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Acute Hepatic Porphyria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Acute Hepatic Porphyria Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Acute Hepatic Porphyria Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • 350 Mg
  • 313 Mg
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
  • Others
Companies covered
  • Alnylam Pharmaceuticals
  • Recordati Rare Diseases

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Acute Hepatic Porphyria Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Acute Hepatic Porphyria Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Acute Hepatic Porphyria Drug Market Dynamics
  1. 2.1 Acute Hepatic Porphyria Drug Industry Trends
  2. 2.2 Acute Hepatic Porphyria Drug Industry Drivers
  3. 2.3 Acute Hepatic Porphyria Drug Industry Opportunities and Challenges
  4. 2.4 Acute Hepatic Porphyria Drug Industry Restraints
3 Acute Hepatic Porphyria Drug Market by Company
  1. 3.1 Global Acute Hepatic Porphyria Drug Company Revenue Ranking in 2025
  2. 3.2 Global Acute Hepatic Porphyria Drug Revenue by Company (2021-2026)
  3. 3.3 Global Acute Hepatic Porphyria Drug Company Ranking (2024-2026)
  4. 3.4 Global Acute Hepatic Porphyria Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Acute Hepatic Porphyria Drug Company Product Type and Application
  6. 3.6 Global Acute Hepatic Porphyria Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Acute Hepatic Porphyria Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Acute Hepatic Porphyria Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Acute Hepatic Porphyria Drug Market by Type
  1. 4.1 Acute Hepatic Porphyria Drug Type Introduction
  2. 4.1.1 350 Mg
  3. 4.1.2 313 Mg
  4. 4.2 Global Acute Hepatic Porphyria Drug Sales Value by Type
  5. 4.2.1 Global Acute Hepatic Porphyria Drug Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Acute Hepatic Porphyria Drug Sales Value by Type (2021-2032)
  7. 4.2.3 Global Acute Hepatic Porphyria Drug Sales Value Share by Type (2021-2032)
5 Acute Hepatic Porphyria Drug Market by Application
  1. 5.1 Acute Hepatic Porphyria Drug Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.1.4 Others
  6. 5.2 Global Acute Hepatic Porphyria Drug Sales Value by Application
  7. 5.2.1 Global Acute Hepatic Porphyria Drug Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Acute Hepatic Porphyria Drug Sales Value by Application (2021-2032)
  9. 5.2.3 Global Acute Hepatic Porphyria Drug Sales Value Share by Application (2021-2032)
6 Acute Hepatic Porphyria Drug Regional Value Analysis
  1. 6.1 Global Acute Hepatic Porphyria Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Acute Hepatic Porphyria Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Acute Hepatic Porphyria Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Acute Hepatic Porphyria Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Acute Hepatic Porphyria Drug Sales Value (2021-2032)
  7. 6.3.2 North America Acute Hepatic Porphyria Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Acute Hepatic Porphyria Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Acute Hepatic Porphyria Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Acute Hepatic Porphyria Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Acute Hepatic Porphyria Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Acute Hepatic Porphyria Drug Sales Value (2021-2032)
  16. 6.6.2 South America Acute Hepatic Porphyria Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Acute Hepatic Porphyria Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Acute Hepatic Porphyria Drug Sales Value Share by Country, 2025 VS 2032
7 Acute Hepatic Porphyria Drug Country-level Value Analysis
  1. 7.1 Global Acute Hepatic Porphyria Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Acute Hepatic Porphyria Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Acute Hepatic Porphyria Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Acute Hepatic Porphyria Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Acute Hepatic Porphyria Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Acute Hepatic Porphyria Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Acute Hepatic Porphyria Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alnylam Pharmaceuticals
  2. 8.1.1 Alnylam Pharmaceuticals Company Information
  3. 8.1.2 Alnylam Pharmaceuticals Business Overview
  4. 8.1.3 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alnylam Pharmaceuticals Acute Hepatic Porphyria Drug Product Portfolio
  6. 8.1.5 Alnylam Pharmaceuticals Recent Developments
  7. 8.2 Recordati Rare Diseases
  8. 8.2.1 Recordati Rare Diseases Company Information
  9. 8.2.2 Recordati Rare Diseases Business Overview
  10. 8.2.3 Recordati Rare Diseases Acute Hepatic Porphyria Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Recordati Rare Diseases Acute Hepatic Porphyria Drug Product Portfolio
  12. 8.2.5 Recordati Rare Diseases Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst